Early Detection of Primary Biliary Cholangitis in Adults With Positive Anti-Mitochondrial Antibodies and Normal Liver Enzyme Levels

What this Trial Is About

Researchers are studying Primary Biliary Cholangitis PBC in adults aged 18 to 80 years who have positive Anti-Mitochondrial Antibodies AMA but normal levels of Alkaline Phosphatase ALP. The goal is to identify early signs of PBC by looking for factors that may predict the disease in this group. This observational study focuses on finding ways to diagnose PBC before it progresses, which is important for timely care. Eligible participants are adults with positive AMA at a titer of 140 or higher and consistently normal ALP levels. During the study, participants may undergo a liver biopsy and specific blood tests to assess liver health and immune activity. These tests include reviewing liver tissue according to Scheuers criteria and measuring markers like the Enhanced Liver Fibrosis ELF Score, Fibroblast Growth Factor 19, Tumor Necrosis Factor-alpha, cytokines, and Transforming Growth Factor-beta. Participants will be evaluated once at enrollment with these tests and biopsy to gather detailed information about their liver condition. The study collects samples and performs analyses to understand the presence and progression of PBC in people with positive AMA but normal liver enzymes. The findings aim to improve early diagnosis and monitoring approaches for patients who may develop this disease.

Early Diagnosis of Primary Biliary Cholangitis (PBC) in Patients With Positive Anti-Mitochondrial Antibodies (AMA) and Normal Alkaline Phosphatase (ALP)